Share on StockTwits

Investment analysts at RBC Capital boosted their target price on shares of Aerie Pharmaceuticals (NASDAQ:AERI) from $36.00 to $41.00 in a note issued to investors on Thursday. The firm currently has an “outperform” rating on the stock. RBC Capital’s price target suggests a potential upside of 88.77% from the stock’s previous close.

In other Aerie Pharmaceuticals news, major shareholder Group Holdings (Sbs) Advis Tpg unloaded 1,000,000 shares of the stock on the open market in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $25.17, for a total value of $25,170,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

A number of other firms have also recently commented on AERI. Analysts at Canaccord Genuity initiated coverage on shares of Aerie Pharmaceuticals in a research note on Thursday, July 3rd. They set a “buy” rating and a $40.00 price target on the stock. Analysts at Needham & Company LLC raised their price target on shares of Aerie Pharmaceuticals from $26.00 to $37.00 in a research note on Thursday, June 26th. They now have a “buy” rating on the stock.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded down 6.42% on Thursday, hitting $21.72. 348,963 shares of the company’s stock traded hands. Aerie Pharmaceuticals has a 52 week low of $10.25 and a 52 week high of $29.71. The stock’s 50-day moving average is $21.03 and its 200-day moving average is $19.24. The company’s market cap is $509.1 million.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings data on Monday, May 12th. The company reported ($0.28) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.07. Analysts expect that Aerie Pharmaceuticals will post $-1.43 EPS for the current fiscal year.

Aerie Pharmaceuticals, Inc is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.